VIVXF (Avivagen) Common Stock: $26.43 Mil (As of Jul. 2023)


What is Avivagen Common Stock?

Avivagen VIVXF -99.00% Common Stock is $26.43 Mil as of Jul. 2023.

Avivagen's quarterly common stock declined from Jan. 2023 ($26.00 Mil) to Apr. 2023 ($25.90 Mil) but then increased from Apr. 2023 ($25.90 Mil) to Jul. 2023 ($26.43 Mil).

Avivagen's annual common stock increased from Oct. 2020 ($20.09 Mil) to Oct. 2021 ($25.59 Mil) but then declined from Oct. 2021 ($25.59 Mil) to Oct. 2022 ($25.49 Mil).

Avivagen Common Stock Historical Data

* Premium members only.

The historical data trend for Avivagen's Common Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Avivagen Common Stock Chart

Avivagen Annual Data
Trend Oct13 Oct14 Oct15 Oct16 Oct17 Oct18 Oct19 Oct20 Oct21 Oct22
Common Stock
Get a 7-Day Free Trial Premium Member Only Premium Member Only 17.66 18.16 20.09 25.59 25.49

Avivagen Quarterly Data
Oct18 Jan19 Apr19 Jul19 Oct19 Jan20 Apr20 Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23
Common Stock Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 26.57 25.49 26.00 25.90 26.43

Avivagen Common Stock Calculation

Common stock is listed on the Balance Sheet at the par value of the total shares outstanding of a company.

The par value of common stocks is meaningless. It is usually set at an absurdly low number.

Frequently Asked Questions Learn more about Common Stock →
What does a Common Stock of $26.43 Mil mean?
Avivagen (VIVXF) has a Common Stock of $26.43 Mil as of Jul. 2023. Common Stock is the par value of a company's shares outstanding, as listed on the balance sheet. View historical data on Avivagen and its competitors.
Is Avivagen's Common Stock too high?
Avivagen's current Common Stock is $26.43 Mil.
How does Avivagen's Common Stock compare to DMKPQ and MJNE?
Avivagen's Common Stock of $26.43 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Common Stock for a Drug Manufacturers company?
A good Common Stock depends on the Drug Manufacturers industry context. However, Common Stock should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Common Stock mean?
A high Common Stock can signal that a stock is expensive relative to its fundamentals. Common Stock is the par value of a company's shares outstanding, as listed on the balance sheet. View historical data on Avivagen and its competitors. Avivagen's current Common Stock is $26.43 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Avivagen stock overvalued right now?
Avivagen (VIVXF) has a current Common Stock of $26.43 Mil. The current Common Stock is $26.43 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Common Stock calculated?
Common Stock is calculated from a company's financial statements. For Avivagen (VIVXF), the current Common Stock is $26.43 Mil as of Jul. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Avivagen Business Description

Address 100 Sussex Drive, Ottawa, ON, CAN, K1A 0R6
Avivagen Inc OxC-beta technology is derived from Avivagen discoveries about Beta-carotene and other carotenoids, compounds that give certain fruits and vegetables their bright colours. Through support of immune function the technology provides a non-antibiotic means of promoting health and growth. OxCbeta Livestock is a proprietary product shown to be an effective and economic alternative to the antibiotics commonly added to livestock feeds. Avivagen's OxC-beta Livestock product is safe, effective and could fulfill the global mandate to remove all in-feed antibiotics as growth promoters.